期刊
BIOLOGICAL & PHARMACEUTICAL BULLETIN
卷 36, 期 6, 页码 889-891出版社
PHARMACEUTICAL SOC JAPAN
DOI: 10.1248/bpb.b13-00107
关键词
polyethyleneglycol; PEGylation; anti-polyethyleneglycol antibody response; protein; liposome; nanocarrier
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan [23390012]
- Grants-in-Aid for Scientific Research [23390012] Funding Source: KAKEN
In contrast to the general assumption that polyethyleneglycol (PEG)-conjugated substances lack immunogenicity and antigenic, it has been reported that they can elicit antibodies against PEG (mainly anti-PEG immunoglobulin M (IgM)). In patients, the presence of anti-PEG antibodies may limit therapeutic efficacy of PEGylated substances as a consequence of inducing rapid clearance of and neutralizing biological activity of the substances. Here, we introduce specific examples of PEGylated substances including several PEGylated proteins and PEGylated particles (PEGylated nanocarriers) which induce anti-PEG antibody responses. Finally, we emphasize that the immunogenicity of PEGylated substances should be tested in the development stage and that the titer of anti-PEG antibodies in patients should be pre-screened and monitored prior to and throughout a course of treatment with a PEGylated substance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据